Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Arrhythmogenic Cardiomyopathy

Cardiovascular

Arrhythmogenic Cardiomyopathy (ACM) Clinical Trials

Also called ACM, arrhythmogenic right ventricular cardiomyopathy, ARVC

Arrhythmogenic cardiomyopathy (ACM, formerly called arrhythmogenic right ventricular cardiomyopathy or ARVC) is a rare genetic heart disease characterized by fibro-fatty replacement of cardiac myocardium, predominantly affecting the right ventricle though biventricular involvement develops with disease progression. The disease is usually caused by mutations in genes for desmosomal proteins, the structures that hold heart muscle cells together. Mutations in PKP2 (plakophilin-2) are the most common cause, and a gene change is found in about 60% of patients.

In plain words, arrhythmogenic cardiomyopathy is a genetic heart disease where healthy heart muscle is slowly replaced by fat and scar tissue. It mostly affects the right side of the heart and can cause irregular heartbeats and fainting spells.

Get an email when new Arrhythmogenic Cardiomyopathy trials open or the FDA decides. Get alerts

Arrhythmogenic Cardiomyopathy

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Arrhythmogenic Cardiomyopathy yet.

Arrhythmogenic Cardiomyopathy has no FDA-approved medicines, 24 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Arrhythmogenic Cardiomyopathy

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Arrhythmogenic Cardiomyopathy

These mutations impair intercellular adhesion, leading to myocyte death and replacement by fibrous and fatty tissue. Progressive conduction system disease develops with altered electrical properties facilitating re-entrant arrhythmias.

Keep reading about Arrhythmogenic Cardiomyopathy

Patients present with palpitations and syncope from ventricular arrhythmias, or catastrophically with sudden cardiac death. Characteristic ECG findings include epsilon waves (small electrical deflections after QRS), low QRS voltages, and T wave inversions in anterior leads. Cardiac imaging shows right ventricular dilatation and regional wall motion abnormalities with intramural fat infiltration visible on cardiac MRI. Arrhythmias are often exercise-induced and may be exercise-triggered, making risk stratification critical. Progressive disease leads to biventricular involvement and congestive heart failure.

What are the symptoms of Arrhythmogenic Cardiomyopathy?

These are common symptoms of Arrhythmogenic Cardiomyopathy, and how strong they are varies from person to person.

  • Palpitations and syncope from arrhythmias
  • Epsilon waves on ECG
  • Sudden cardiac death risk
  • Progressive dyspnea and fatigue
  • Right ventricular dysfunction on imaging
  • Atrial fibrillation

Who gets Arrhythmogenic Cardiomyopathy?

Arrhythmogenic cardiomyopathy often manifests in adolescence or early adulthood with palpitations or syncope, though disease presentation varies considerably. Some individuals remain asymptomatic and are identified through family screening.

The condition affects males and females, though males are at notably higher risk for sudden cardiac death. Autosomal dominant inheritance is most common, with approximately 50% of offspring of affected parents inheriting mutations. Rare autosomal recessive forms exist, particularly in populations with consanguinity.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new Arrhythmogenic Cardiomyopathy medicines are in trials?

Investigational medicines Trial Friend tracks for Arrhythmogenic Cardiomyopathy, with trial results, safety findings and where each one stands.

How to get help paying for Arrhythmogenic Cardiomyopathy treatment

Charity funds and drugmaker programs for Arrhythmogenic Cardiomyopathy, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 16, 2026.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Arrhythmogenic Cardiomyopathy

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Arrhythmogenic Cardiomyopathy resources

Reputable organizations and medical references for learning more about Arrhythmogenic Cardiomyopathy, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Arrhythmogenic Cardiomyopathy

Use this Arrhythmogenic Cardiomyopathy clinical trial finder to see the 17 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 7 test a treatment and 12 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

24 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT06352307

Clinical Phenotypes, Natural History, and Long-Term Outcomes of Arrhythmogenic Cardiomyopathy: The STARTER Registry

Sponsor: First Affiliated Hospital Xi'an Jiaotong University

The goal of this observational study is to describe the clinical phenotypes, natural history, and long-term outcomes of arrhythmogenic cardiomyopathy (ACM) in patients of all ages.

The main questions it aims to answer are:

Ages not specified1 location
Started Apr 2024Updated todayEst. Dec 2050 (~24y 1m)
RecruitingObservational study, no treatment givenRecently updatedNCT07354646

The Application of T1 Mapping in Real-World

Intervention: Magnetic Resonance Imaging with Contrast

Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better i...

Ages not specified1 location
Started Mar 2020Updated 1 week agoEst. Dec 2026 (12 days)
RecruitingTreatment trialPhase 2Recently updatedNCT06922994

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

Intervention: Atorvastatin 80 mg/day, Placebo atorvastatin

Sponsor: Centro Cardiologico Monzino

The goal of this clinical trial is to learn if Atorvastatin 80 mg is effective to avoid functional right ventricular deterioration in patients affected by Arrhythmogenic Cardiomyopathy. It will also learn about the safety of Atorvastatin 80 mg in this type of patients. The main questions it aims to answer are:

Ages 18 Years+
Started Mar 2025Updated 3 weeks agoEst. Dec 2026 (~1 month)
RecruitingObservational study, no treatment givenRecently updatedNCT07849764

Subcutaneous Implantable Cardioverter-defibrillator (S-ICD) Eligibility Over Time in Arrhythmogenic Cardiomyopathy

Intervention: Subcutaneous ICD ECG screening

Sponsor: University of Sao Paulo

The goal of this observational study is to learn whether adults with arrhythmogenic cardiomyopathy, an inherited heart muscle disease that can cause dangerous heart rhythms, remain eligible for a subcutaneous implantable cardioverter-defibrillator (S-ICD) over time.

Ages 18 Years+1 location
Started Jul 2026Updated 1 month agoEst. Jul 2028 (~1y 8m)
RecruitingObservational study, no treatment givenRecently updatedNCT06409585

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

Intervention: 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR, Echocardiogram, Cardiac MRI

Sponsor: University of Edinburgh

Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these condi...

Ages 30 Years to 90 Years1 location
Started May 2023Updated 2 months agoEst. Aug 2027 (~8 months)
Find Arrhythmogenic Cardiomyopathy trials near you, ranked by distance →
Active trial locations18 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+10 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Arrhythmogenic Cardiomyopathy trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run an Arrhythmogenic Cardiomyopathy foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Arrhythmogenic Cardiomyopathy patient communities

Facebook groups, Reddit communities and YouTube channels where Arrhythmogenic Cardiomyopathy patients, caregivers and advocacy groups talk.

Companies developing Arrhythmogenic Cardiomyopathy treatments

Drugmakers that list Arrhythmogenic Cardiomyopathy in their rare disease portfolio, 2 in all.

Questions people ask about Arrhythmogenic Cardiomyopathy